No Data
Silexion Therapeutics Shareholders Approve Capital Increase, Reverse Split
Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)
12 Health Care Stocks Moving In Tuesday's After-Market Session
Silexion Therapeutics Shares Are Trading Lower. The Company Announced the Submission of a Clinical Trial Application to Germany for Its Planned Phase 2/3 Clinical Trial of Its Lead, SiRNA Product Candidate, SIL204.
Silexion Advances SIL204 to EU Phase 2/3 Pancreatic Trial
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer